Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan add-on to ravulizumab or eculizumab in pediatric PNH with clinically significant extravascular hemolysis
2024-511795-32-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline in hemoglobin at Week 12. Planned start Feb 2025; status: authorised.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2024-511795-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511795-32-00.